OneDigital Investment Advisors LLC Buys New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

OneDigital Investment Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,021 shares of the biopharmaceutical company’s stock, valued at approximately $281,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALNY. Metis Global Partners LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 47.2% during the 3rd quarter. Metis Global Partners LLC now owns 4,380 shares of the biopharmaceutical company’s stock worth $1,205,000 after acquiring an additional 1,405 shares during the last quarter. Zions Bancorporation N.A. lifted its stake in Alnylam Pharmaceuticals by 2,860.0% during the third quarter. Zions Bancorporation N.A. now owns 592 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 572 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Plato Investment Management Ltd boosted its holdings in shares of Alnylam Pharmaceuticals by 33.2% in the 3rd quarter. Plato Investment Management Ltd now owns 4,702 shares of the biopharmaceutical company’s stock worth $1,292,000 after purchasing an additional 1,173 shares in the last quarter. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 1,906 shares of the biopharmaceutical company’s stock valued at $524,000 after buying an additional 190 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $244.89 on Friday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company’s 50-day moving average is $273.54 and its 200 day moving average is $236.84. The stock has a market capitalization of $31.59 billion, a P/E ratio of -93.47 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the prior year, the company earned $1.15 earnings per share. The business’s quarterly revenue was down 33.3% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ALNY. Scotiabank upped their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Finally, TD Cowen lifted their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.